[Drug-induced neuroleptic malignant syndrome].
Kawanishi
Chiaki
C
Department of Psychiatry, Yokohama City University School of Medicine
Furuno
Taku
T
Kishida
Ikuko
I
D015415:Biomarkers / Q000097:blood; D001971:Bromocriptine / Q000627:therapeutic use; D052283:Creatine Kinase, MM Form / Q000097:blood; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D011110:Polymorphism, Genetic; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000009:adverse effects*; D012015:Reference Standards; D012307:Risk Factors; D013997:Time Factors
D015415:Biomarkers; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D011619:Psychotropic Drugs; D001971:Bromocriptine; D019389:Cytochrome P-450 CYP2D6; D052283:Creatine Kinase, MM Form; D003620:Dantrolene